HKU Scholars Hub: Browsing DSpace

Browsing by Author Hassanein, T

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 13 of 13

	Title	Author(s)	Issue Date	Views
	An integrated analysis of phase 2,3 SOF and LDV/SOF trials for the treatment of GT6 HCV Infection Proceeding/Conference:Hepatology International	Lai, CL Chuang, WL Hassanein, T Kowdley, KV Lawitz, E Gao, B Mo, HM Hyland, R Yang, JC De-Oertel, S Natha, M Brainard, D Knox, SJ McHutchison, JG Chan, HLY Gane, EJ	2016	80
	Analysis of longer-term safety profile of the hepatitis B virus core inhibitor ABI-H0731 in an open label extension study Proceeding/Conference:Hepatology	Jacobson, IM Ma, X Nguyen, T Schiff, ER Yuen, RMF Hann, HWL Sulkowski, MS Nahass, RG Ramji, A Agarwal, K Park, JS Ayoub, WS Gane, EJ Knox, S Alves, K Li, YF Stamm, LM Weilert, F Bennett, M Han, SHB Ravendhran, N Chan, S Kwo, PY Elkhashab, M Hassanein, T Fung, SK Bae, H Lalezari, JP Dieterick, DT	2020	12
	Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection Proceeding/Conference:Journal of Hepatology	Fung, S Sulkowski, M Lalezari, J Schiff, ER Dieterich, D Hassanein, T Kwo, P Elkhashab, M Nahass, R Ayoub, W Han, SH Bonacini, M Alves, K Zayed, H Huang, Q Colonno, R Knox, S Ramji, A Bennett, M Gane, E Ravendhran, N Park, J Jacobson, I Bae, H Chan, S Hann, HW Ma, X Nguyen, T Yuen, RMF	2020	49
	Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study Proceeding/Conference:Journal of Hepatology	Yuen, RMF Agarwal, K Ma, X Nguyen, T Schiff, ER Hann, HW Dieterich, D Nahass, R Park, J Chan, S Han, SH Gane, E Bennett, M Alves, K Zayed, H Huang, Q Colonno, R Knox, S Stamm, L Bonacini, M Jacobson, I Ayoub, W Weilert, F Ravendhran, N Ramji, A Kwo, P Elkhashab, M Hassanein, T Bae, H Lalezari, J Fung, S Sulkowski, M	2020	40
	Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection Proceeding/Conference:Journal of Hepatology	Agarwal, K Niu, J Ding, Y Gane, E Nguyen, T Alves, K Evanchick, M Zayed, H Huang, Q Knox, S Stamm, L Colonno, R Hassanein, T Kim, DJ Lim, YS Yuen, RMF	2020	36
	Continued therapy with ABI-H0731+NRTI results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg positive patients Proceeding/Conference:Hepatology	Sulkowski, MS Agarwal, K Fung, SK Yuen, RMF Ma, XL Lalezari, JP Nguyen, TT Bae, HS Schiff, ER Hassanein, T Hann, HWL Elkhashab, M Dieterich, DT Kwo, PY Nahass, R Ramji, A Park, JS Ravendhran, N Chan, S Weilert, F Han, SHB Ayoub, WS Gane, EJ Jacobson, IM Bennett, M Bonacini, M Zayed, H Alves, K Huey, V Huang, Q Ruby, E Qiang, DM Knox, S Colonno, R	2019	54
	Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B. Poster Presentation (SAT866) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Sulkowski, MS Fung, SK Ma, XL Nguyen, TT Schiff, ER Hann, H-W L Dieterich, DT Nahass, RG Park, JS Chen, S Han, S-H B Gane, EJ Bennett, M Yan, R Liu, JM Ma, J Knox, SJ Stamm, LM Bonacini, M Jacobson, IM Ayoub, WS Weilert, F Ravendhran, N Ramji, A Kwo, PY Elkhashab, M Hassanein, T Bae, HS Lalezari, K Yuen, RMF	2022	2
	Integrated analysis of controlled clinical trials evaluating efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C genotype 6 (HCV GT 6) Proceeding/Conference:Journal of Hepatology	Nguyen, MH Chuang, WL Hassanein, T Kowdley, K Lai, CL Chan, HLY Feld, JJ Letterio, C Hahambis, TA Llewellyn, J De-Oertel, S Brainard, DM Lawitz, EJ Gane, EJ	2017	44
	Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients Proceeding/Conference:Journal of Hepatology	Ma, XL Lalezari, J Nguyuen, T Bae, Ho Schiff, ER Fung, S Yuen, RMF Hassanein, T Hann, HW Elkhashab, M Dieterich, D Sulkowski, M Kwo, P Nahass, R Agarwal, K Ramji, A Park, J Ravendhran, N Chan, S Weilert, F Han, SH Ayoub, W Gane, E Jacobson, I Bennett, M Huang, Q Yan, R Huey, V Ruby, E Liaw, S Colonno, R Lopatin, U	2019	74
	Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection Journal:Journal of Hepatology	Sulkowski, MS Agarwal, K Ma, XL Nguyen, TT Schiff, ER Hann, H-W L Dieterich, DT Nahass, RG Park, JS Chan, S Han, S-H B Gane, EJ Bennett, M Alves, K Evanchik, M Yan, R Huang, Q Lopatin, U Colonno, R Ma, J Knox, SJ Stamm, LM Bonacini, M Jacobson, IM Ayoub, WS Weilert, F Ravendhran, N Ramj, A Kwo, PY Elkhashab, M Hassanein, T Bae, HS Lalezari, JP Fung, SK Yuen, RMF	2022
	Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection Journal:Journal of Hepatology	Yuen, RMF Agarwal, K Ma, XL Nguyen, TT Schiff, ER Hann, H-WL Dieterich, DT Nahass, RT Park, JS Chan, S Han, S-H B Gane, EJ Bennett, M Alves, K Evanchik, M Yan, R Huang, Q Lopatin, U Colonno, R Ma, J Knox, SJ Stamm, LM Bonacini, M Jacobson, IM Ayoub, WS Weilert, F Ravendhran, N Ramji, A Kwo, PY Elkhashab, M Hassanein, T Bae, HS Lalezari, JP Fung, SK Sulkowski, MS	2022
	The second-generation hepatitis B virus (HBV) core inhibitor (CI) ABI-H2158 is associated with potent antiviral activity in a 14-day monotherapy study in HBeAg-positive patients with chronic hepatitis B (CHB) Proceeding/Conference:Hepatology	Yuen, RMF Agarwal, K Gane, EJ Nguyen, TT Hassanein, T Kim, DJ Alves, K Zayed, H Qiang, DM Ruby, E Evanchik, M Huang, Q Knox, S Colonno, R on behalf of ABI-H2158 Study Team	2019	29
	Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos (t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection Proceeding/Conference:Journal of Hepatology	Gane, E SulkowskI, M Ma, X Nguyen, T Hann, HW Hassanein, T Elkhashab, M Chan, S Nahass, R Bennett, M Park, J Jacobson, I Bonacini, M Ma, J Yan, R Knox, SJ Stamm, L Ramji, A Han, SHB Ayoub, W Ravendhran, N Kwo, PY Dieterich, D Bae, H Schiff, ER Lalezari, J Fung, S Yuen, RMF	2021	11

Showing results 1 to 13 of 13